LONDON, July 24 (Reuters) - GlaxoSmithKline Plc, the world’s second biggest drugmaker, has signed a $25 million-plus deal with the Harvard Stem Cell Institute to harness stem cell technology for the development of new medicines.
LONDON, July 24 (Reuters) - GlaxoSmithKline Plc, the world’s second biggest drugmaker, has signed a $25 million-plus deal with the Harvard Stem Cell Institute to harness stem cell technology for the development of new medicines.
